Major Indian hospital stocks, including Apollo Hospitals and Max Healthcare, dropped on October 12 after the Supreme Court questioned the government's limited focus on drug price caps. Investors are concerned that potential broader regulations could lower pharmacy profits, which are a key income stream for hospital chains.
Indian hospital stocks faced a sharp correction on October 12, 2026, as the Supreme Court challenged the current regulatory approach to medicine pricing. Shares of major chains such as Apollo Hospitals, Max Healthcare, Fortis Healthcare, and Aster DM Healthcare declined between 3% and 6% during the trading session. This market movement reflects investor anxiety regarding potential government mandates that could disrupt the pharmacy revenue models of these healthcare providers.
During the hearing, the Supreme Court bench questioned why the government limits its strict price caps primarily to anti-cancer medications. The judges highlighted a significant gap between the wholesale cost of medicines and the final retail prices charged to patients in hospital pharmacies. The court expressed dissatisfaction with the current framework, which allows hospitals to operate with high trade margins, and asked why comprehensive price controls are not being applied to a wider range of therapeutic categories.
The regulatory focus on pharmacy operations creates uncertainty for investors. Hospital chains often operate in-house pharmacies, which are a significant contributor to their overall profit margins. The court has previously criticized the practice of hospitals mandating that patients purchase medicines exclusively from their own pharmacies. If the judiciary compels the government to expand price caps beyond anti-cancer drugs, it could lead to margin pressure for the entire sector. Industry estimates suggest that a broader pricing framework could potentially impact operating profits, with some analysts noting a risk of 2% to 5% impact on EBITDA if strict caps are enforced across more categories.
The government has already implemented a 30% cap on trade margins for non-scheduled anti-cancer drugs, but the Supreme Court's latest comments suggest that this may only be the beginning of a larger regulatory shift. Investors are now closely monitoring the next hearing in this matter, which is scheduled for October 27, 2026. Until there is more clarity on whether these price caps will be expanded to other categories, the sector may continue to face volatility as the market weighs the risk of stricter price controls against the industry's existing business practices.